Ribeiro P A, Scavetta K, Oh C, Al-Zaibag M, Jutzy K R, Caldron R, Marsa R J
Loma Linda University Medical Center, Loma Linda, CA 92354, USA.
Chest. 2000 Sep;118(3):750-5. doi: 10.1378/chest.118.3.750.
To assess the long-term clinical outcome of treating patients with coronary artery disease and obstructed saphenous vein grafts (SVGs) with stents deployed by oversized balloon catheters.
The study included 89 of 92 consecutive patients who had 121 SVG stent implants (average, 1.4 stents per patient). We aimed at achieving a negative stenosis using oversized balloons to achieve a catheter to artery ratio of 1.1:1, and a 100% follow-up at 24+/-14 months (range, 0 to 54 months) was achieved.
As 3 of 92 patients died during hospital admission, the study follow-up population consisted of 89 of 92 patients (mean age, 67+/-10 years). The age of the SVGs was 10+/-4 years.
We implanted 118 Palmaz-Schatz and 3 Gianturco-Roubin stents. Procedural success was achieved in 87 of 92 patients (94.5%; < 50% stenosis, and no death, Q-wave acute myocardial infarction, or coronary artery bypass graft [CABG]). Mean SVG stenosis diameter was reduced from 80+/-13% to -11+/-12% (p<0.001) and mean luminal diameter increased from 0.6+/-0.5 mm to 3.3+/-0.8 mm (p<0.001). At follow-up, angina pectoris had developed in 42 of 89 patients (47%), acute myocardial infarction in 12 of 89 patients (14%), reperformed CABG in 12 of 89 patients (14%), cardiac death in 10 of 89 patients (11%), and unrelated death in 6 of 89 patients (7%). Coronary angiography was performed in 37 of 89 patients (42%), with restenosis in 16 of 37 patients (43%) and disease progression at other sites in 11 of 37 patients (30%). Only 25 of 89 patients (28%) experienced event-free survival at follow-up.
Despite high procedural success and excellent angiographic results with oversized balloon catheters, the long-term clinical outcome of SVG stent implantation is suboptimal.
评估使用超大球囊导管置入支架治疗冠状动脉疾病和隐静脉桥血管(SVG)闭塞患者的长期临床结局。
该研究纳入了92例连续患者中的89例,这些患者共植入了121个SVG支架(平均每位患者植入1.4个支架)。我们旨在使用超大球囊使狭窄程度变为阴性,使导管与血管比例达到1.1:1,并在24±14个月(范围为0至54个月)时实现100%的随访。
92例患者中有3例在住院期间死亡,研究随访人群包括92例患者中的89例(平均年龄67±10岁)。SVG的使用年限为10±4年。
我们植入了118个Palmaz-Schatz支架和3个Gianturco-Roubin支架。92例患者中有87例(94.5%)手术成功(狭窄程度<50%,且无死亡、Q波急性心肌梗死或冠状动脉旁路移植术[CABG])。SVG的平均狭窄直径从80±13%降至-11±12%(p<0.001),平均管腔直径从0.6±0.5毫米增加到3.3±0.8毫米(p<0.001)。随访时,89例患者中有42例(47%)发生心绞痛,89例患者中有12例(14%)发生急性心肌梗死,89例患者中有12例(14%)再次进行CABG,89例患者中有10例(11%)心源性死亡,89例患者中有6例(7%)非相关性死亡。89例患者中有37例(42%)接受了冠状动脉造影,37例患者中有16例(43%)发生再狭窄,37例患者中有11例(30%)其他部位病情进展。89例患者中只有25例(28%)在随访时无事件生存。
尽管使用超大球囊导管手术成功率高且血管造影结果良好,但SVG支架植入的长期临床结局并不理想。